EMEND CAPSULE

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

APREPITANT

Доступна с:

MERCK CANADA INC

код АТС:

A04AD12

ИНН (Международная Имя):

APREPITANT

дозировка:

80MG

Фармацевтическая форма:

CAPSULE

состав:

APREPITANT 80MG

Администрация маршрут:

ORAL

Штук в упаковке:

2

Тип рецепта:

Prescription

Терапевтические области:

NEUROKININ-1 RECEPTOR ANTAGONISTS

Обзор продуктов:

Active ingredient group (AIG) number: 0152292001; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2007-08-24

Характеристики продукта

_ _
_EMEND_
®
_(aprepitant capsules)_
_ _
_Page 1 of 40_
PRODUCT MONOGRAPH
EMEND
®
aprepitant capsules
80 and 125 mg
Neurokinin 1 (NK
1
) receptor antagonist
MERCK CANADA INC.
16750 route Transcanadienne
Kirkland, QC H9H 4M7
Canada
www.merck.ca
Date of Revision:
January 22, 2014
SUBMISSION CONTROL NO: 168159
_ _
_EMEND_
®
_(aprepitant capsules)_
_ _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................15
ACTION AND CLINICAL PHARMACOLOGY
............................................................16
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
................................................................................20
PHARMACEUTICAL INFORMATION
..........................................................................20
CLINICAL TRIALS
..........................................................................................................20
DETAIL